Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carglumic Acid Market
Carglumic Acid Market size was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1% during the forecast period. The growing prevalence of metabolic diseases is anticipated to be among primary factor propelling the growth of the market.
The rising incidences of metabolic diseases globally, including metabolic syndrome, type 2 diabetes mellitus, hypertension, and non-alcoholic fatty liver disease (NAFLD) are a growing concern, with significant increases observed in prevalence rates over the years. According to the Centers for Disease Control and Prevention (CDC), nearly half of adults in the U.S. have hypertension, affecting an estimated 119.9 million adults.
Additionally, the World Health Organization (WHO) emphasizes the importance of early diagnosis through regular check-ups and blood tests to prevent the worst effects of type 2 diabetes. This rise in the prevalence of such metabolic conditions is anticipated as a key factor contributing to the growth of the market.
Carglumic acid is a medication used for the treatment of hyperammonemia, a condition characterized by elevated levels of ammonia in the blood. Hyperammonemia can be caused by various metabolic disorders, including urea cycle disorders. Carglumic acid works by promoting the excretion of ammonia in the urine, thereby reducing its concentration in the blood.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Carglumic Acid Market Size in 2023: | USD 148.6 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2024 – 2032 CAGR: | 7.1% |
2024 – 2032 Value Projection: | USD 280 Million |
Historical Data for: | 2018 – 2023 |
No. of Pages: | 100 |
Tables, Charts & Figures: | 136 |
Segments covered: | Dosage Form, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|